Filing Flows › Comparisons › PLUR vs BEAM
Pluri vs Beam Therapeutics: PLUR and BEAM compared
Pluri is the larger company: $335K of revenue in its latest quarter (Q4 FY26) against $307K for Beam Therapeutics (Q3 2026). Pluri is growing faster (-16% against -97% a year earlier).
Where the money goes: PLUR and BEAM
Pluri (PLUR) · Q4 FY26
Pluri, Q4 FY26: revenue $335K (-16% year over year), net loss $6.2M, operating cash flow −$4.4M. The chart follows the revenue to costs, profit and cash.
Beam Therapeutics (BEAM) · Q3 2026
Beam Therapeutics, Q3 2026: revenue $307K (-97% year over year), net loss $134M, operating cash flow −$111M. The chart follows the revenue to costs, profit and cash.
| Pluri (PLUR) | Beam Therapeutics (BEAM) | |
|---|---|---|
| Latest quarter | Q4 FY26 | Q3 2026 |
| Revenue | $335K | $307K |
| Revenue growth, Y/Y | -16% | -97% |
| Operating margin | n/m | n/m |
| Net earnings | −$6.2M | −$134M |
| Operating cash flow | −$4.4M | −$111M |
Questions
Which is bigger, Pluri or Beam Therapeutics?
Pluri is the larger company: $335K of revenue in its latest quarter (Q4 FY26) against $307K for Beam Therapeutics (Q3 2026).
Is Pluri or Beam Therapeutics growing faster?
Pluri is growing faster (-16% against -97% a year earlier).
More: Pluri earnings · how Pluri makes money · Beam Therapeutics earnings · how Beam Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Sep 10, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.